Gates Foundation Forms an Alliance with Global Pharma Companies to Develop PAN-TB Drug Regimen for Tuberculosis

 Gates Foundation Forms an Alliance with Global Pharma Companies to Develop PAN-TB Drug Regimen for Tuberculosis

Gates Foundation Forms an Alliance with Global Pharma Companies to Develop PAN-TB Drug Regimen for Tuberculosis

Shots:

  • GSK, Evotec, J&J, Otsuka, the Bill & Melinda Gates Medical Research Institute and its foundation have launched the ‘PAN-TB collaboration’ project to collaboratively accelerate the development of novel TB treatment regimens
  • The global collaboration will focus on developing a new regimen with the drug candidates that demonstrated efficacy in its P-II studies with limited or no drug resistance to achieve the global eradication of the disease
  • The PAN-TB collaboration is a first-of-its-kind collaboration among philanthropic, non-profit and private sectors to facilitate the development of an investigational drug regimen for treating all forms of TB

Click here ­to­ read full press release/ article | Ref: GSK | Image: Infectious Disease Advisor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post